These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 34771077)

  • 21. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.
    Zhang B; Zhang X; Tang B; Zheng P; Zhang Y
    Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
    Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
    Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
    [No Abstract]   [Full Text] [Related]  

  • 23. Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation.
    Moerkens M; Zhang Y; Wester L; van de Water B; Meerman JH
    BMC Cancer; 2014 Apr; 14():283. PubMed ID: 24758408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. O-GlcNAcylation-inducing treatments inhibit estrogen receptor α expression and confer resistance to 4-OH-tamoxifen in human breast cancer-derived MCF-7 cells.
    Kanwal S; Fardini Y; Pagesy P; N'tumba-Byn T; Pierre-Eugène C; Masson E; Hampe C; Issad T
    PLoS One; 2013; 8(7):e69150. PubMed ID: 23935944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of UDP-glucuronosyltransferase 2B15 gene expression by the major active metabolites of tamoxifen, 4-hydroxytamoxifen and endoxifen, in breast cancer cells.
    Chanawong A; Hu DG; Meech R; Mackenzie PI; McKinnon RA
    Drug Metab Dispos; 2015 Jun; 43(6):889-97. PubMed ID: 25795461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IL-1β induced methylation of the estrogen receptor ERα gene correlates with EMT and chemoresistance in breast cancer cells.
    Jiménez-Garduño AM; Mendoza-Rodríguez MG; Urrutia-Cabrera D; Domínguez-Robles MC; Pérez-Yépez EA; Ayala-Sumuano JT; Meza I
    Biochem Biophys Res Commun; 2017 Aug; 490(3):780-785. PubMed ID: 28645612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-484 suppresses endocrine therapy-resistant cells by inhibiting KLF4-induced cancer stem cells in estrogen receptor-positive cancers.
    Wei Y; Li H; Qu Q
    Breast Cancer; 2021 Jan; 28(1):175-186. PubMed ID: 32865695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
    Xiong H; Jin X; You C
    Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells.
    Stender JD; Nwachukwu JC; Kastrati I; Kim Y; Strid T; Yakir M; Srinivasan S; Nowak J; Izard T; Rangarajan ES; Carlson KE; Katzenellenbogen JA; Yao XQ; Grant BJ; Leong HS; Lin CY; Frasor J; Nettles KW; Glass CK
    Mol Cell; 2017 Mar; 65(6):1122-1135.e5. PubMed ID: 28306507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.
    Plaza-Menacho I; Morandi A; Robertson D; Pancholi S; Drury S; Dowsett M; Martin LA; Isacke CM
    Oncogene; 2010 Aug; 29(33):4648-57. PubMed ID: 20531297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
    Li J; Lu M; Jin J; Lu X; Xu T; Jin S
    Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.
    Cittelly DM; Das PM; Spoelstra NS; Edgerton SM; Richer JK; Thor AD; Jones FE
    Mol Cancer; 2010 Dec; 9():317. PubMed ID: 21172025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stemness Phenotype in Tamoxifen Resistant Breast Cancer Cells May be Induced by Interactions Between Receptor Tyrosine Kinases and ERα-66.
    Farahmand L; Mansouri S; Jafarbeik-Iravani N; Teymourzadeh A; Majidzadeh-A K
    Recent Pat Anticancer Drug Discov; 2018; 13(3):302-307. PubMed ID: 29512469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MiR 221/222 as New Players in Tamoxifen Resistance.
    Alamolhodaei NS; Behravan J; Mosaffa F; Karimi G
    Curr Pharm Des; 2016; 22(46):6946-6955. PubMed ID: 27809747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.
    Miller TE; Ghoshal K; Ramaswamy B; Roy S; Datta J; Shapiro CL; Jacob S; Majumder S
    J Biol Chem; 2008 Oct; 283(44):29897-903. PubMed ID: 18708351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.
    Rao X; Di Leva G; Li M; Fang F; Devlin C; Hartman-Frey C; Burow ME; Ivan M; Croce CM; Nephew KP
    Oncogene; 2011 Mar; 30(9):1082-97. PubMed ID: 21057537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
    Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor α signaling in breast cancer.
    Zhao Y; Deng C; Lu W; Xiao J; Ma D; Guo M; Recker RR; Gatalica Z; Wang Z; Xiao GG
    Mol Med; 2011; 17(11-12):1233-41. PubMed ID: 21826373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miRNA-128 and miRNA-223 regulate cholesterol-mediated drug resistance in breast cancer.
    Palma GBH; Kaur M
    IUBMB Life; 2023 Sep; 75(9):743-764. PubMed ID: 37070323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.